Transcarent Completes Acquisition of Accolade for $621 Million

April 8, 2025

Transcarent agreed to acquire Accolade for $7.03 per share in cash, valuing the deal at approximately $621 million. The merger combines Transcarent’s AI-powered WayFinding and care experiences with Accolade’s health advocacy, expert medical opinions, and virtual primary care platform.

Buyers
Transcarent, General Catalyst, Glen Tullman's 62 Ventures, J.P. Morgan
Targets
Accolade
Location
California, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.